These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38929568)

  • 41. Do statins enhance the antitumor effect of trastuzumab emtansine (T-DM1)?: Real-life cohort.
    Akyildiz A; Guven DC; Yildirim HC; Ismayilov R; Yilmaz F; Tatar OD; Chalabiyev E; Kus F; Yalcin S; Aksoy S
    Medicine (Baltimore); 2023 May; 102(18):e33677. PubMed ID: 37145008
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Case series of docetaxel, trastuzumab, and pertuzumab (DTP) as first line anti-HER2 therapy and ado-trastuzumab emtansine (T-DM1) as second line for recurrent or metastatic HER2-positive salivary duct carcinoma.
    Uijen MJM; Lassche G; van Engen-van Grunsven ACH; Driessen CML; van Herpen CML
    Oral Oncol; 2022 Feb; 125():105703. PubMed ID: 34995931
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: The Phase III KAITLIN Study.
    Krop IE; Im SA; Barrios C; Bonnefoi H; Gralow J; Toi M; Ellis PA; Gianni L; Swain SM; Im YH; De Laurentiis M; Nowecki Z; Huang CS; Fehrenbacher L; Ito Y; Shah J; Boulet T; Liu H; Macharia H; Trask P; Song C; Winer EP; Harbeck N
    J Clin Oncol; 2022 Feb; 40(5):438-448. PubMed ID: 34890214
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Primary results of ELAINA: a randomized, multicenter, open-label, phase III study of the efficacy and safety of trastuzumab emtansine
    Wang X; Li W; Yin Y; Tong Z; Zhang Q; Zheng H; Shao Z; Li H; Yang J; Feng J; Wu F; Lamour F; Restuccia E; Jiang Z
    Transl Breast Cancer Res; 2023; 4():3. PubMed ID: 38751488
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Population pharmacokinetics and exposure-response of trastuzumab emtansine in advanced breast cancer previously treated with ≥2 HER2-targeted regimens.
    Chen SC; Quartino A; Polhamus D; Riggs M; French J; Wang X; Vadhavkar S; Smitt M; Hoersch S; Strasak A; Jin JY; Girish S; Li C
    Br J Clin Pharmacol; 2017 Dec; 83(12):2767-2777. PubMed ID: 28733983
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer.
    Baselga J; Lewis Phillips GD; Verma S; Ro J; Huober J; Guardino AE; Samant MK; Olsen S; de Haas SL; Pegram MD
    Clin Cancer Res; 2016 Aug; 22(15):3755-63. PubMed ID: 26920887
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Primary predictors of survival outcomes for HER2-positive advanced breast cancer patients initiating ado-trastuzumab emtansine.
    Hopkins AM; Rowland A; Logan JM; Sorich MJ
    Breast; 2019 Aug; 46():90-94. PubMed ID: 31170589
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study.
    Sanglier T; Shim J; Lamarre N; Peña-Murillo C; Antao V; Montemurro F
    Breast; 2023 Jun; 69():441-450. PubMed ID: 36709091
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Trastuzumab Biosimilar (HLX02), Pertuzumab Plus Chemotherapy in Patients with HER2-Positive Metastatic Breast Cancer after Progression of Trastuzumab: A Prospective, Phase II Study.
    Zhang R; Liu X; Song G; Zhang Y; Li H
    Cancer Res Treat; 2024 Jul; 56(3):795-801. PubMed ID: 38147816
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A real-world study of treatment sequences and second-line clinical outcomes in patients with HER2-positive metastatic breast cancer in US community practice.
    Varghese D; Cruz GI; Johanson C; Toland L; Miranda M; Faherty EC; Harland D; Kaplan HG
    Int J Clin Oncol; 2024 Jun; 29(6):780-789. PubMed ID: 38528295
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long term outcome data from the EORTC 75111-10114 ETF/BCG randomized phase II study: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer, followed by T-DM1 after progression.
    Wildiers H; Meyskens T; Marréaud S; Lago LD; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Meulemans B; Sousa B; Poncet C; Brain E
    Breast; 2022 Aug; 64():100-111. PubMed ID: 35636341
    [TBL] [Abstract][Full Text] [Related]  

  • 52. T-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study.
    Schettini F; Conte B; Buono G; De Placido P; Parola S; Griguolo G; Fabi A; Bighin C; Riccardi F; Cianniello D; De Laurentiis M; Puglisi F; Pelizzari G; Bonotto M; Russo S; Frassoldati A; Pazzola A; Montemurro F; Lambertini M; Guarneri V; Cognetti F; Locci M; Generali D; Conte P; De Placido S; Giuliano M; Arpino G; Del Mastro L
    ESMO Open; 2021 Apr; 6(2):100099. PubMed ID: 33819752
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q.
    Jhaveri KL; Wang XV; Makker V; Luoh SW; Mitchell EP; Zwiebel JA; Sharon E; Gray RJ; Li S; McShane LM; Rubinstein LV; Patton D; Williams PM; Hamilton SR; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
    Ann Oncol; 2019 Nov; 30(11):1821-1830. PubMed ID: 31504139
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase II Study of Weekly Paclitaxel with Trastuzumab and Pertuzumab in Patients with Human Epidermal Growth Receptor 2 Overexpressing Metastatic Breast Cancer: 5-Year Follow-up.
    Wang R; Smyth LM; Iyengar N; Chandarlapaty S; Modi S; Jochelson M; Patil S; Norton L; Hudis CA; Dang CT
    Oncologist; 2019 Aug; 24(8):e646-e652. PubMed ID: 30602614
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparative effectiveness of trastuzumab emtansine versus lapatinib plus chemotherapy for HER2+ metastatic breast cancer.
    Ramagopalan SV; Pisoni R; Zenin A; Rathore LS; Ray J; Sammon C
    J Comp Eff Res; 2021 May; 10(7):595-602. PubMed ID: 33095031
    [TBL] [Abstract][Full Text] [Related]  

  • 56. De-Escalation Strategies in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer (BC): Final Analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early BC HER2- and Hormone Receptor-Positive Phase II Randomized Trial-Efficacy, Safety, and Predictive Markers for 12 Weeks of Neoadjuvant Trastuzumab Emtansine With or Without Endocrine Therapy (ET) Versus Trastuzumab Plus ET.
    Harbeck N; Gluz O; Christgen M; Kates RE; Braun M; Küemmel S; Schumacher C; Potenberg J; Kraemer S; Kleine-Tebbe A; Augustin D; Aktas B; Forstbauer H; Tio J; von Schumann R; Liedtke C; Grischke EM; Schumacher J; Wuerstlein R; Kreipe HH; Nitz UA
    J Clin Oncol; 2017 Sep; 35(26):3046-3054. PubMed ID: 28682681
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy.
    Jain S; Shah AN; Santa-Maria CA; Siziopikou K; Rademaker A; Helenowski I; Cristofanilli M; Gradishar WJ
    Breast Cancer Res Treat; 2018 Sep; 171(2):371-381. PubMed ID: 29850984
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Exposure-response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane.
    Li C; Wang B; Chen SC; Wada R; Lu D; Wang X; Polhamus D; French J; Vadhavkar S; Strasak A; Smitt M; Joshi A; Samant M; Quartino A; Jin J; Girish S
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1079-1090. PubMed ID: 29022084
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Phase 2 Clinical Trial.
    Iyengar NM; Smyth LM; Lake D; Gucalp A; Singh JC; Traina TA; DeFusco P; Fornier MN; Goldfarb S; Jhaveri K; Modi S; Troso-Sandoval T; Patil S; Ulaner GA; Jochelson M; Norton L; Hudis CA; Dang CT
    JAMA Netw Open; 2019 Nov; 2(11):e1916211. PubMed ID: 31774522
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA.
    Krop IE; Lin NU; Blackwell K; Guardino E; Huober J; Lu M; Miles D; Samant M; Welslau M; Diéras V
    Ann Oncol; 2015 Jan; 26(1):113-119. PubMed ID: 25355722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.